Innate Pharma Financials
| IPH Stock | EUR 2.01 0.08 4.15% |
Innate |
Understanding current and past Innate Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Innate Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Innate Pharma's assets may result in an increase in income on the income statement.
Please note, the presentation of Innate Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Innate Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Innate Pharma's management manipulating its earnings.
Innate Pharma Stock Summary
Innate Pharma competes with Genfit, Nanobiotix, Cellectis, and AB Science. Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company was founded in 1999 and is based in Marseille, France. INNATE PHARMA operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 191 people.| Foreign Associate | USA |
| Instrument | France Stock View All |
| Exchange | Euronext Paris |
| ISIN | FR0010331421 |
| Business Address | 117, Avenue de |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.innate-pharma.com |
| Phone | 33 4 30 30 30 30 |
| Currency | EUR - Euro |
You should never invest in Innate Pharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Innate Stock, because this is throwing your money away. Analyzing the key information contained in Innate Pharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Innate Pharma Key Financial Ratios
Innate Pharma's financial ratios allow both analysts and investors to convert raw data from Innate Pharma's financial statements into concise, actionable information that can be used to evaluate the performance of Innate Pharma over time and compare it to other companies across industries.| Return On Equity | -0.17 | |||
| Return On Asset | -0.043 | |||
| Target Price | 6.7 | |||
| Number Of Employees | 213 | |||
| Beta | 0.33 |
Innate Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Innate Pharma's current stock value. Our valuation model uses many indicators to compare Innate Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Innate Pharma competition to find correlations between indicators driving Innate Pharma's intrinsic value. More Info.Innate Pharma is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Innate Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Innate Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Innate Pharma Systematic Risk
Innate Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Innate Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Innate Pharma correlated with the market. If Beta is less than 0 Innate Pharma generally moves in the opposite direction as compared to the market. If Innate Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Innate Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Innate Pharma is generally in the same direction as the market. If Beta > 1 Innate Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Innate Pharma February 6, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Innate Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Innate Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Innate Pharma based on widely used predictive technical indicators. In general, we focus on analyzing Innate Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Innate Pharma's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.08 | |||
| Information Ratio | 0.0761 | |||
| Maximum Drawdown | 27.06 | |||
| Value At Risk | (5.26) | |||
| Potential Upside | 10.17 |
Complementary Tools for Innate Stock analysis
When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |